

SILLS CUMMIS & GROSS
Newark, NJ 07102

SIDLEY AUSTIN LLP
Washington, DC 20005

*Counsel for Defendants JANSSEN BIOTECH, INC.,
JANSSEN ONCOLOGY, INC., JANSSEN
RESEARCH & DEVELOPMENT, LLC, and
JOHNSON & JOHNSON*

WALSH PIZZI O'REILLY FALANGA LLP
Newark, NJ 07102

WILMER CUTLER PICKERING HALE AND
DORR LLP
Washington, DC 20006

*Counsel for Defendant BTG INTERNATIONAL
LIMITED*

(Counsel Detail Provided on Signature Page)

**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

UNITED STATES OF AMERICA, STATES OF
CALIFORNIA, COLORADO, CONNECTICUT,
DELAWARE, FLORIDA, GEORGIA, HAWAII,
ILLINOIS, INDIANA, IOWA, LOUISIANA,
MICHIGAN, MINNESOTA, MONTANA,
NEVADA, NEW JERSEY, NEW MEXICO, NEW
YORK, NORTH CAROLINA, OKLAHOMA,
RHODE ISLAND, TENNESSEE, TEXAS,
VERMONT, AND WASHINGTON; THE
COMMONWEALTHS OF MASSACHUSETTS
AND VIRGINIA; and THE DISTRICT OF
COLUMBIA,

ex rel. ZACHARY SILBERSHER,

Plaintiffs,

vs.

JANSSEN BIOTECH, INC., JANSSEN
ONCOLOGY, INC., JANSSEN RESEARCH &
DEVELOPMENT, LLC, JOHNSON &
JOHNSON, and BTG INTERNATIONAL

Defendants.

Civil Action No. 19-12107 (KM)
(JBC)

**DEFENDANTS' REQUEST FOR
JUDICIAL NOTICE IN SUPPORT
OF DEFENDANTS' JOINT
MOTION TO DISMISS SECOND
AMENDED COMPLAINT**

Document electronically filed

Defendants Janssen Biotech, Inc., Janssen Oncology, Inc., Janssen Research & Development, LLC, Johnson & Johnson (“J&J Defendants”), and BTG International Limited (“BTG”) (collectively, “Defendants”), pursuant to Federal Rule of Evidence 201, respectfully request that this Court take judicial notice of the following documents, true and correct copies or excerpts of which are attached:

Exhibit A – U.S. Patent No. 5,604,213 (issued Feb. 18, 1997).

Exhibit B – U.S. Patent No. 8,822,438 (issued Sept. 2, 2014).

Exhibit C – Applicant Arguments, Notice of Appeal, and Other Reference-Appeal Documents, submitted June 4, 2013, for U.S. Patent Application No. 13/034,430 (filed Feb. 24, 2011), *available at* <https://portal.uspto.gov/pair/PublicPair>.

Exhibit D – Petition, *Amerigen Pharm., Ltd. v. Janssen Oncology, Inc.*, IPR2016-00286 (P.T.A.B. Dec. 12, 2015), *available at* <https://ptab.uspto.gov/#/login>.

Exhibit E – Petition, *Mylan Pharm., Inc. v. Janssen Oncology, Inc.*, IPR2016-01332 (P.T.A.B. June 30, 2016), *available at* <https://ptab.uspto.gov/#/login>.

Exhibit F – Petition, *Wockhardt Bio AG v. Janssen Oncology, Inc.*, IPR2016-01582 (P.T.A.B. Aug. 10, 2016), *available at* <https://ptab.uspto.gov/#/login>.

Exhibit G – Michael S. Cookson et. al, *Castration-Resistant Prostate Cancer: AUA Guideline*, AMERICAN UROLOGY ASSOCIATION EDUCATION AND RESEARCH, INC. (2013).

Exhibit H – GSA Drugs, Pharmaceuticals & Hematology Related Products Solicitation, 01 – Solicitation Document, Standing Solicitation No. M5-Q50A-03-R8.

Exhibit I – Specification, submitted Feb. 24, 2011, for U.S. Patent Application No. 13/034,430 (filed Feb. 24, 2011), *available at* <https://portal.uspto.gov/pair/PublicPair>.

Exhibit J – Excerpt from Certified File Wrapper of U.S. Patent No. 8,822,438, Patent Application No. 13/034,340 (filed Feb. 24, 2011).

Exhibit K – Johnson & Johnson, Form 10-Q (Nov. 4, 2016).

Exhibit L – Johnson & Johnson, Form 10-Q (Aug. 4, 2016).

Exhibit M – Johnson & Johnson, Form 10-Q (May 9, 2016).

Exhibit N – Johnson & Johnson, Form 10-K (Feb. 24, 2016).

Exhibit O – Elaine A. Mostaghel, *Abiraterone in the Treatment of Metastatic Castration-Resistant Prostate Cancer*, CANCER MANAGEMENT RESEARCH (2012), <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912049/>.

Exhibit P – *Patent Board Grants Inter Partes Review of Cancer-Fighting Therapy*, 24-1 MEALEY’S(R) LITIG. REP.: PATENTS 12 (2016).

Exhibit Q – Dr. Cary Millner & Kunyong Yang, *United States: PTAB Institutes Separate IPR Proceedings Filed By Codefendants, Finding That The Later IPR Proceeding Was Not Barred by 35 U.S.C. § 325(d)*, PTAB Litigation Blog, MONDAQ BUS. BRIEFING (Feb. 7, 2017).

Exhibit R – *Zytiga To Face Challenges*, BUSINESS MONITOR ONLINE (Nov. 3, 2016).

Exhibit S – Jan Berger et al., *How Drug Life-Cycle Management Patent Strategies May Impact Formulary Management*, 22 (16 supp.) AJMC (Jan. 20, 2017), <https://www.ajmc.com/journals/supplement/2016/how-drug-life-cycle-management-patent-strategies-may-impact-formulary-management/a636-article>.

Exhibit T – Silas Inman, *FDA Approves Pre-Chemo Enzalutamide for mCRPC*, ONCLIVE (Sept. 10, 2014), <https://www.onclive.com/web-exclusives/fda-approves-pre-chemo-enzalutamide-for-mcrpc>.

Exhibit U – Donald L. Trump, *FDA Approves Enzalutamide for Metastatic Castration-Resistant Prostate Cancer*, HEMONC TODAY (Sept. 25, 2012), <https://www.healio.com/hematology-oncology/prostate-cancer/news/print/hemonc-today/%7B9c47a439-aef9-4380-bdce-0e6843a2d524%7D/fda-approves-enzalutamide-for-metastatic-castration-resistant-prostate-cancer>.

Exhibit V – Amit Bahl et al., *Second-Line Treatment Options in Metastatic Castration-Resistant Prostate Cancer: A Comparison of Key Trials with Recently Approved Agents*, CANCER TREATMENT REVIEWS (Aug. 16, 2013), <https://doi.org/10.1016/j.ctrv.2013.06.008>.

Exhibit W – H. Lee Mofflitt Cancer Ctr. & Res. Inst., *Researchers Identify Inhibitor that Overcomes Drug Resistance in Prostate Cancer*, SCIENCEDAILY (June 12, 2017), www.sciencedaily.com/releases/2017/06/170612124417.htm.

Exhibit X – Emmanuel S. Antonakaris, *Current Understanding of Resistance to Abiraterone and Enzalutamide in Advanced Prostate Cancer*, CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY (May 2016), <http://www.hematologyandoncology.net/archives/may-2016/current-understanding-of-resistance-to-abiraterone-and-enzalutamide-in-advanced-prostate-cancer/>.

Exhibit Y – Andrew Pollack, *New Drug For Prostate Cancer Gets F.D.A. Nod*, N.Y. TIMES (Aug. 31, 2012), <https://www.nytimes.com/2012/09/01/business/fda-approves-prostate-cancer-drug.html>.

Exhibit Z – Naoki Terada et al., *Exploring the Optimal Sequence of Abiraterone and Enzalutamide in Patients with Chemotherapy-Naïve Castration-Resistant Prostate Cancer: The Kyoto-Baltimore Collaboration*, 24 INT’L J. OF UROLOGY (Apr. 28, 2017), <https://doi.org/10.1111/iju.13346>.

Exhibit AA – Dennis Thompson, *Early Chemo May Boost Survival in Advanced Prostate Cancer*, WEBMD (May 14, 2015), <https://www.webmd.com/prostate-cancer/news/20150514/early-chemo-may-boost-survival-in-advanced-prostate-cancer#1>.

Exhibit BB – Todd Campbell, *Can Xtandi Become the Go-To Prostate Drug?*, AOL FINANCE (Sept. 20, 2013), <https://www.aol.com/article/finance/2013/09/20/can-xtandi-become-the-go-to-prostate-drug/20725994/#>.

Exhibit CC – Andrew Pollack, *New Drugs Fight Prostate Cancer, but at High Cost*, N.Y. TIMES (June 27, 2011), <https://www.nytimes.com/2011/06/28/health/28prostate.html>.

Exhibit DD – *What Is ZYTIGA® (Abiraterone Acetate)?*, ZYTIGA® (archived October 15, 2017), <https://web.archive.org/web/20171015195728/https://www.zytiga.com/>.

Exhibit EE – *How should I take XTANDI?*, XTANDI® (archived October 6, 2017), <https://web.archive.org/web/20171006005848/https://www.xtandi.com/>.

Exhibit FF – *Why make JEVTANA your next step?*, JEVTANA® (archived October 5, 2017), <https://web.archive.org/web/20171005083102/http://www.learnaboutjevtana.com/>.

Exhibit GG – Dep't of Veterans Affairs, National Acquisition Center (CCST), Item Details: 57894-0150-12, <https://www.vendorportal.ecms.va.gov/NAC/Pharma/Details?NDC=57894019506&CNT=36F79719D0217> (last visited Sept. 12, 2019).

Exhibit HH – U.S. Dep't of Veterans Affairs, National Acquisition Center (CCST), Item Details: 57894-0195-06; <https://www.vendorportal.ecms.va.gov/NAC/Pharma/Details?NDC=57894015012&CNT=36F79719D0217> (last visited Sept. 12, 2019).

Exhibit II – Maxx Chatsko, *Can Zytiga Build on a Historic 2012?*, THE MOTLEY FOOL (Feb. 19, 2013), <https://www.fool.com/investing/general/2013/02/19/can-zytiga-build-on-historic.aspx>.

Exhibit JJ – Jillian Dabney, *Analyzing Medivation's Growth Opportunity with Xtandi*, YAHOO! FINANCE (May 12, 2016), <https://finance.yahoo.com/news/analyzing-medivation-growth-opportunity-xtandi-133503575.html>.

Exhibit KK – Charles J. Ryan, *mCRPC Treatment: The Right Treatment for the Right Patient at the Right Time: Everyday Urology*, EUROTODAY (June 2016), https://www.urotoday.com/images/journal_issues/everyday-urology-volume-1-issue-4.pdf.

Exhibit LL – Da Hee Han, *New Zytiga Tablet Strength Availability*, MPR (May 17, 2017), <https://www.empr.com/home/news/new-zytiga-tablet-strength-available/>.

Exhibit MM – Christian Nordqvist, *Xtandi (Enzalutamide) Approved For Late Stage Prostate Cancer*, FDA, MEDICALNEWSTODAY (Sept. 3, 2012), <https://www.medicalnewstoday.com/articles/249785.php>.

Exhibit NN – *Natco Pharma files new drug applications with USFDA*, LIVEMINT (Feb. 10, 2015), <https://www.livemint.com/Companies/PMLycu8RnqNhVacGWcYjaP/Natco-Pharma-files-new-drug-applications-with-USFDA.html>.

Exhibit OO – U.S. Patent Application No. 13/034,340, Publication No. US-2011-0144016-A1 (Published date June 6, 2011) (Alan H. Auerbach, applicant).

RELEVANT AUTHORITY

When evaluating a motion to dismiss, courts may “review documents attached to the complaint and matters of public record” in addition to the complaint itself. *Nationwide Mut. Ins. Co. v. Caris*, 170 F. Supp. 3d 740, 745 (D.N.J. 2016). Courts may also “judicially notice a fact that is not subject to reasonable dispute,” because it “can be accurately and readily determined from sources whose accuracy cannot reasonably be questioned.” Fed. R. Evid. 201(b).

The attached Exhibits fall within categories of documents that courts have recognized as judicially noticeable. Courts may take judicial notice of such materials to determine whether a qualifying public disclosure occurred, without converting the motion to dismiss into one for summary judgment. *See, e.g., U.S. ex rel. Hunt v. Merck-Medco Managed Care, L.L.C.*, 336 F. Supp. 2d 430, 446 n.12 (E.D. Pa. 2004); *U.S. ex rel. Spay v. CVS Caremark Corp.*, 913 F. Supp. 2d 125, 142 (E.D. Pa. 2012); *U.S. ex rel. Ambrosecchia v. Paddock Labs., LLC*, 855 F.3d 949, 954–55 (8th Cir. 2017) (“amended public disclosure bar is appropriately resolved on a motion to dismiss, even assuming that it no longer poses a jurisdictional question” and “[i]n evaluating whether the public disclosure bar applies, [courts] may consider ... items subject to judicial notice.”).

Exhibits A through H are judicially noticeable because they are documents relevant to “matters incorporated by reference or integral to the claim.” *Buck v. Hampton Twp. Sch. Dist.*, 452 F.3d 256, 260 (3d Cir. 2006). Exhibits A and B are the two patents upon which Relator’s Second Amended Complaint (“SAC”) relies. Exhibit C is Defendants’ June 4, 2013 patent-prosecution filing (“the June 4 Submission”) submitted in Application No. 13/034,340 (“the ’340 Application”) and referenced in the SAC. *See* SAC ¶¶ 82, 87. The June 4 Submission is central to the SAC because the SAC alleges that the submission contained fraudulent misrepresentations

and/or omissions to the United States Patent & Trademark Office (“USPTO”). Exhibits D, E, and F are *inter partes* review petitions cited by Relator in the SAC. SAC ¶ 101. Exhibit G is an American Urology Association guideline from 2013 on which Relator premises one of his allegations. *Id.* ¶ 87(d). Exhibit H is a General Services Administration solicitation document from which Relator quotes in support of his claims. *Id.* ¶ 114.

Exhibits I through Z and AA through FF, as well as Exhibit OO are judicially noticeable because they are “matters of public record.” *Buck*, 452 F.3d at 260. Exhibits I and J are documents that were submitted by the J&J Defendants during the ’438 patent prosecution and are available via the USPTO’s Public Patent Application Information Retrieval System (“PAIR”). Similarly, Exhibit OO is the Notice of Publication for the ’340 Application and available on Public PAIR. Courts may take judicial notice of information available from PAIR. *E.g., TransCardiac Therapeutics, Inc. v. Yoganathan*, 15 F. Supp. 3d 1364, 1372 n.12 (N.D. Ga. 2014); *RB Rubber Prods., Inc. v. ECORE Int’l, Inc.*, No. 3:11-cv-319-AC, 2012 WL 860416, at *5 (D. Or. Mar. 13, 2012). Exhibits K, L, M, and N are publicly filed 10-Q and 10-K disclosures. SEC filings are subject to judicial notice. *See Spay*, 913 F. Supp. 2d at 139.

Exhibits O through Z, AA through CC, and II through NN are online articles or reports that are available to the public. Defendants request these documents to be judicially noticed not for the truth of the information, but for “what was known and in existence in the public realm at the time.” *Id.* at 142.

Exhibits DD, EE, and FF are screenshots of three webpages from October 2017, accessed via the Wayback Machine, an internet archive that reflects how a given webpage appeared at a prior point in time. “Courts have taken judicial notice of the contents of web pages available through Wayback Machine as facts that can be accurately and readily determined from sources

whose accuracy cannot reasonably be questioned.” *Erickson v. Neb. Mach. Co.*, No. 15-CV-01147-JD, 2015 WL 4089849, at *1 n.1 (N.D. Cal. July 6, 2015); *see also Williams v. Ying Zhou*, No. Civ. No. 14-5544, 2019 WL 1379876, at *4 (D.N.J. Mar. 27, 2019).

Exhibits GG and HH are webpages published by the Department of Veterans Affairs’ website that reflect that Zytiga is offered for sale to the government on a Federal Supply Schedule. The Court may take judicial notice of documents available from reliable sources on the internet, such as websites run by Government agencies. *See, e.g., In re Wellbutrin SR/Zyban Antitrust Litig.*, 281 F. Supp. 2d 751, 754 n.2 (E.D. Pa. 2003) (taking judicial notice of reports published on the FDA website).

Because all of the exhibits referenced herein are judicially noticeable, Defendants respectfully request the Court to take judicial notice of each of the attached Exhibits for purposes of showing the existence of the Exhibits, their dates of publication, and the public availability of their contents.

Dated: September 13, 2019

SILLS CUMMIS & GROSS P.C.

By: /s/ Jeffrey J. Greenbaum
JEFFREY J. GREENBAUM
jgreenbaum@sillscummis.com
GREGORY E. REID
greid@sillscummis.com
One Riverfront Plaza
Newark, New Jersey 07102
Phone: (973) 643-5297
Facsimile: (973) 643-6500

SIDLEY AUSTIN LLP

GORDON D. TODD (*pro hac vice*)
gtodd@sidley.com
KIMBERLY LEAMAN (*pro hac vice*)
kimberly.leaman@sidley.com
1501 K Street, N.W.
Washington, DC 20005

*Attorneys for Defendants Janssen
Biotech, Inc., Janssen Oncology, Inc.,
Janssen Research & Development, LLC,
and Johnson & Johnson*

Respectfully submitted,

WALSH PIZZI O'REILLY FALANGA LLP

By: /s/ Liza M. Walsh
LIZA M. WALSH
lwalsh@walsh.law
Three Gateway Center
100 Mulberry Street, 15th Floor
Newark, New Jersey 07102
Phone: (973) 757-1100
Facsimile: (973) 757-1090

**WILMER CUTLER PICKERING HALE AND
DORR LLP**

JONATHAN G. CEDARBAUM (*pro hac vice*)
jonathan.cedarbaum@wilmerhale.com
1875 Pennsylvania Avenue, N.W.
Washington, DC 20006
Telephone: (202) 663-6315
Facsimile: (202) 663-6363
*Attorneys for Defendant
BTG International Limited*